{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T20:49:34Z","timestamp":1774039774696,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA249734"],"award-info":[{"award-number":["R01 CA249734"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["T32 CA165990"],"award-info":[{"award-number":["T32 CA165990"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA177558"],"award-info":[{"award-number":["P30 CA177558"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32 CA165990"],"award-info":[{"award-number":["T32 CA165990"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA249734"],"award-info":[{"award-number":["R01 CA249734"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013140","name":"Colorectal Cancer Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013140","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.neo.2026.101283","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T19:25:43Z","timestamp":1770319543000},"page":"101283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Inhibition of fatty acid synthase enhances therapeutic efficacy and delays acquired resistance to BRAF-targeted therapy in colorectal cancer"],"prefix":"10.1016","volume":"73","author":[{"given":"Mariah E.","family":"Geisen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josiane W.","family":"Tessmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney O.","family":"Kelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0399-2466","authenticated-orcid":false,"given":"Daheng","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8627-8887","authenticated-orcid":false,"given":"Abu Saleh Mosa","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen J.","family":"Beswick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmine","family":"Baca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5700-6954","authenticated-orcid":false,"given":"Stephanie","family":"Rock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill M.","family":"Kolesar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yekaterina Y.","family":"Zaytseva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2026.101283_bib0001","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1242\/dmm.027441","article-title":"MicroRNAs in the etiology of colorectal cancer: pathways and clinical implications","volume":"10","author":"Strubberg","year":"2017","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.neo.2026.101283_bib0002","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1200\/JCO.21.02541","article-title":"BRAF-mutated advanced colorectal cancer: a rapidly changing therapeutic landscape","volume":"40","author":"Ciombor","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2026.101283_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.166061","article-title":"BRAF paradox breakers PLX8394, PLX7904 are more effective against BRAFV600\u0395 CRC cells compared with the BRAF inhibitor PLX4720 and shown by detailed pathway analysis","volume":"1867","author":"Koumaki","year":"2021","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.neo.2026.101283_bib0004","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.neo.2026.101283_bib0005","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2026.101283_bib0006","first-page":"877","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. Reply","volume":"382","author":"Kopetz","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2026.101283_bib0007","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41591-018-0274-5","article-title":"RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling","volume":"25","author":"Yao","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.neo.2026.101283_bib0008","unstructured":"Fore Biotherapeutics, Plixorafenib program, 2024."},{"key":"10.1016\/j.neo.2026.101283_bib0009","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/1535-7163.MCT-17-0705","article-title":"Response and resistance to paradox-breaking braf inhibitor in melanomas in vivo and ex vivo","volume":"17","author":"Hartsough","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.neo.2026.101283_bib0010","doi-asserted-by":"crossref","first-page":"24787","DOI":"10.18632\/oncotarget.25361","article-title":"Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer","volume":"9","author":"Zaytseva","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2026.101283_bib0011","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.ebiom.2015.06.020","article-title":"Inhibition of de novo palmitate synthesis by fatty acid synthase induces apoptosis in tumor cells by remodeling cell membranes, inhibiting signaling pathways, and reprogramming gene expression","volume":"2","author":"Ventura","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.neo.2026.101283_bib0012","article-title":"Lipid metabolism and resistance to anticancer treatment","volume":"9","author":"Germain","year":"2020","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.neo.2026.101283_bib0013","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1158\/1078-0432.CCR-19-0253","article-title":"A fatty acid oxidation-dependent metabolic shift regulates the adaptation of BRAF-mutated melanoma to MAPK inhibitors","volume":"25","author":"Aloia","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2026.101283_bib0014","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1038\/s41467-018-04664-0","article-title":"Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy","volume":"9","author":"Talebi","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2026.101283_bib0015","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41416-019-0628-x","article-title":"Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells","volume":"122","author":"Delgado-Goni","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.neo.2026.101283_bib0016","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1476-4598-6-24","article-title":"The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention","volume":"6","author":"Alao","year":"2007","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.neo.2026.101283_bib0017","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/0971-5916.159250","article-title":"Survivin: a molecular biomarker in cancer","volume":"141","author":"Jaiswal","year":"2015","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.neo.2026.101283_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15215243","article-title":"BRAF inhibitors in metastatic colorectal cancer and mechanisms of resistance: a review of the literature","volume":"15","author":"Guerrero","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neo.2026.101283_bib0019","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12943-017-0684-x","article-title":"PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation","volume":"16","author":"Tutuka","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.neo.2026.101283_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.166061","article-title":"BRAF paradox breakers PLX8394, PLX7904 are more effective against BRAFV600Epsilon CRC cells compared with the BRAF inhibitor PLX4720 and shown by detailed pathway analysis","volume":"1867","author":"Koumaki","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.neo.2026.101283_bib0021","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","article-title":"EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib","volume":"2","author":"Corcoran","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.neo.2026.101283_bib0022","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.neo.2026.101283_bib0023","doi-asserted-by":"crossref","first-page":"596","DOI":"10.18632\/oncotarget.13480","article-title":"Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation","volume":"8","author":"Byeon","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2026.101283_bib0024","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jid.2021.10.007","article-title":"Vemurafenib drives epithelial-to-mesenchymal transition gene expression in BRAF inhibitor\u2012resistant BRAF(V600E)\/NRAS(Q61K) melanoma enhancing tumor growth and metastasis in a bioluminescent murine model","volume":"142","author":"Jandova","year":"2022","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.neo.2026.101283_bib0025","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.bbrc.2018.10.137","article-title":"Transforming growth factor alpha promotes tumorigenesis and regulates epithelial-mesenchymal transition modulation in colon cancer","volume":"506","author":"Yu","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neo.2026.101283_bib0026","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020301","article-title":"Lipid metabolism as a targetable metabolic vulnerability in colorectal cancer","volume":"13","author":"Zaytseva","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neo.2026.101283_bib0027","article-title":"Identification of a novel lipid metabolism-related gene signature for predicting colorectal cancer survival","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.neo.2026.101283_bib0028","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.18632\/oncotarget.3130","article-title":"ColoLipidGene: signature of lipid metabolism-related genes to predict prognosis in stage-II colon cancer patients","volume":"6","author":"Vargas","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2026.101283_bib0029","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1158\/0008-5472.CAN-11-4057","article-title":"Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer","volume":"72","author":"Zaytseva","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2026.101283_bib0030","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrc2222","article-title":"Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis","volume":"7","author":"Menendez","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.neo.2026.101283_bib0031","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jbior.2013.09.004","article-title":"Molecular mechanisms of fatty acid synthase (FASN)-mediated resistance to anti-cancer treatments","volume":"54","author":"Wu","year":"2014","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.neo.2026.101283_bib0032","article-title":"Rescue of cell cycle progression in BRAF(V600E) inhibitor-resistant human melanoma by a chromatin modifier","volume":"39","author":"Toress-Collado","year":"2017","journal-title":"Tumour. Biol."},{"key":"10.1016\/j.neo.2026.101283_bib0033","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.4161\/cc.21263","article-title":"Regulation of transcription and chromatin structure by pRB: here, there and everywhere","volume":"11","author":"Talluri","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.neo.2026.101283_bib0034","article-title":"The role of E2F2 in cancer progression and its value as a therapeutic target","volume":"15","author":"Gao","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neo.2026.101283_bib0035","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1172\/JCI57114","article-title":"Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma","volume":"122","author":"Sachdeva","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neo.2026.101283_bib0036","doi-asserted-by":"crossref","first-page":"10473","DOI":"10.1002\/cam4.5783","article-title":"Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer","volume":"12","author":"Xu","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.neo.2026.101283_bib0037","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41416-020-01147-2","article-title":"Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib \u00b1 binimetinib or alpelisib","volume":"124","author":"Huijberts","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.neo.2026.101283_bib0038","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221105022","article-title":"Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR\/BRAF inhibitors","volume":"14","author":"Xu","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.neo.2026.101283_bib0039","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejca.2021.11.018","article-title":"Tumour mutational burden predicts resistance to EGFR\/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer","volume":"161","author":"Randon","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.neo.2026.101283_bib0040","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1038\/s41591-024-03235-9","article-title":"Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial","volume":"30","author":"Kopetz","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.neo.2026.101283_bib0041","first-page":"1486","article-title":"BRAF(V600E) mutation promoted the growth and chemoresistance of colorectal cancer","volume":"13","author":"Ma","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.neo.2026.101283_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010252","article-title":"Upregulation of CD36, a fatty acid translocase, promotes colorectal cancer metastasis by increasing MMP28 and decreasing e-cadherin expression","volume":"14","author":"Drury","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.neo.2026.101283_bib0043","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fonc.2019.00268","article-title":"Diverse mechanisms of BRAF inhibitor resistance in melanoma identified in clinical and preclinical studies","volume":"9","author":"Luebker","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.neo.2026.101283_bib0044","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.3892\/or.2017.5963","article-title":"Phenotype characterization of human melanoma cells resistant to dabrafenib","volume":"38","author":"Cordaro","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.neo.2026.101283_bib0045","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/pcmr.12379","article-title":"miR-200c\/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment","volume":"28","author":"Liu","year":"2015","journal-title":"Pigment. Cell Melanoma Res."},{"key":"10.1016\/j.neo.2026.101283_bib0046","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1074\/mcp.RA117.000486","article-title":"A system-wide approach to monitor responses to synergistic BRAF and EGFR inhibition in colorectal cancer cells","volume":"17","author":"Ressa","year":"2018","journal-title":"Mol. Cell Proteomics"},{"key":"10.1016\/j.neo.2026.101283_bib0047","doi-asserted-by":"crossref","first-page":"18891","DOI":"10.18632\/oncotarget.3783","article-title":"Increased expression of fatty acid synthase provides a survival advantage to colorectal cancer cells via upregulation of cellular respiration","volume":"6","author":"Zaytseva","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2026.101283_bib0048","doi-asserted-by":"crossref","first-page":"30540","DOI":"10.1074\/jbc.M405061200","article-title":"A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2","volume":"279","author":"Knowles","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neo.2026.101283_bib0049","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/carcin\/bgu042","article-title":"Cancer cell-associated fatty acid synthase activates endothelial cells and promotes angiogenesis in colorectal cancer","volume":"35","author":"Zaytseva","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.neo.2026.101283_bib0050","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15205090","article-title":"Unraveling resistance to immunotherapy in MSI-high colorectal cancer","volume":"15","author":"Heregger","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558626000126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558626000126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:55:06Z","timestamp":1774032906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558626000126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":50,"alternative-id":["S1476558626000126"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2026.101283","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of fatty acid synthase enhances therapeutic efficacy and delays acquired resistance to BRAF-targeted therapy in colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2026.101283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101283"}}